Advertisement

Topics

Circassia Ltd Company Profile

04:01 EDT 25th September 2017 | BioPortfolio

Circassia is a specialty biopharmaceutical company focused on developing world-class immunotherapies. These include a new class of T-cell vaccines designed to treat a broad range of allergies, and therapies to combat autoimmune conditions such as rheumatoid arthritis and psoriasis. The Company has made rapid progress since its establishment in 2006, and several of its products are currently in mid- to late-stage development, having successfully completed a number of phase II clinical studies.

Circassia was originally founded to develop and commercialise a range of allergy T-cell vaccines based on the Company’s proprietary ToleroMune® technology, which has the potential to transform current treatment. With its portfolio of allergy T-cell vaccines progressing rapidly through clinical development, Circassia has broadened its pipeline into other areas of immunotherapy. These include treatments for

Circassia is managed by a strong team of life science entrepreneurs and scientists, and is chaired by Sir Richard Sykes, the former Chairman of GlaxoSmithKline. The management team brings a wealth of experience from major pharmaceutical and biotechnology companies as well as the specialty pharmaceutical sector. Circassia is well funded having raised £60m in April 2011 and is supported by a syndicate of leading institutional and venture capital investors.

Location

Magdalen Centre
The Oxford Science Park
Oxford
Oxfordshire
OX4 4GA
UK

Contact

Phone: +44 (0)1865 784574
Fax: +44 (0)1865 784576
Email: Charlesswingland@circassia.co.uk


News Articles [10 Associated News Articles listed on BioPortfolio]

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

Circassia has positive Phase III results from its respiratory pipeline, great news for the company after abandoning its allergy immunotherapies due to clinical failure. Circassia Pharmaceuticals, base...

Circassia Announces Duaklir Successfully Met Primary Endpoints In AMPLIFY Phase III Study In Chronic Obstructive Pulmonary Disease

OXFORD, UNITED KINGDOM--(Marketwired - September 07, 2017) - Circassia Pharmaceuticals Plc (LSE: CIR)(LSE: CIR)Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase I...

Positive lung drug trial opens path to U.S. market for Circassia

LONDON (Reuters) - AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for a submission in the United State...

Circassia Pharmaceuticals PLC Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Updated: 04052017] Prices from USD $350

Circassia Pharmaceuticals PLC Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Circassia Pharmaceuticals PLC Mergers Acquisitions MA, Partnerships Alliance...

Touchstone Plays Tough As IP Group Ups Bid To £490m

One of the key attractions is Touchstone's holdings in Imperial College spin-offs such as Cell Medica, Circassia Pharmaceuticals and TopiVert...   

Circassia Pharmaceuticals Plc CIR Financial and Strategic SWOT Analysis Review [Updated: 15052017] Prices from USD $300

SummaryCircassia Pharmaceuticals plc Circassia is a specialty biopharmaceutical company that develops treatments for allergy and respiratory diseases such as asthma. The company's product NIOX VERO, i...

Circassia Pharmaceuticals Plc CIR Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryCircassia Pharmaceuticals plc Circassia is a pharmaceutical company that develops treatments for allergy and respiratory diseases such as asthma. The company's product includes NIOX VERO, which...

Circassia Announces Duaklir(R) Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease

OXFORD, UNITED KINGDOM -- (Marketwired) -- 09/07/17 -- Circassia Pharmaceuticals Plc (LSE: CIR) (LSE: CIR) Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Stud...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Circassia Ltd

Circassia is a specialty biopharmaceutical company focused on developing world-class immunotherapies. These include a new class of T-cell vaccines designed to treat a broad range of allergies, and t...

More Information about "Circassia Ltd" on BioPortfolio

We have published hundreds of Circassia Ltd news stories on BioPortfolio along with dozens of Circassia Ltd Clinical Trials and PubMed Articles about Circassia Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Circassia Ltd Companies in our database. You can also find out about relevant Circassia Ltd Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...


Corporate Database Quicklinks



Searches Linking to this Company Record